

TRANSGENE BIOTEK LIMITED
68,69,&70, ANRICH INDUSTRIAL AREA
BOLLARAM, MEDAK DISTRICT

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.03.2014

(Rs. In Lakhs)

	Particulars	Quarter ended 31.03.2014	Quarter ended 31.12.2013	Quarter ended 31.03.2013	For the year ended 31.03.2014	For Previous year ended 31.03.2013
		Audited	UnAudited	Audited	Audited	Audited
1	(a) Net Sales/Income from Operations	28.25	12.58	61.46	98.11	1503.05
	(b) Other Operating Income				-	-
	2. Expenditure					
	a. Increase/decrease in stock in trade and work in progress	0.00	0.15	38.44	14.75	47.03
	b. Consumption of raw materials	1.57	5.05	(8.67)	9.28	11.14
2	c. Purchase of traded goods	-	-	(0.03)	0	1366.42
	d. Employees cost	72.21	9.09	(15.89)	102.43	54.25
	e. Depreciation	1,448.26	91.39	73.89	1721.55	101.51
	f. Other expenditure	36.22	25.36	55.21	128.57	107.78
	Total	1,558.25	131.04	142.95	1976.57	1688.13
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	(1530.00)	(118.46)	(81.49)	(1,878.46)	(185.09)
4	Other Income	40.00	46.00	3.42	80.00	5.95
5	Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	(1490.00)	(72.46)	(78.08)	(1,798.46)	(179.13)
6	Finance Cost	0.05	(0.02)	(9.37)	0.05	19.78
7	Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	(1,490.05)	(72.44)	(68.71)	(1,798.51)	(198.92)
8	Exceptional items*	-		-	0	0.00
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	(1,490.05)	(72.44)	(68.71)	(1,798.51)	(198.92)
10	Tax expense	-		-	0.00	0.00
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	(1490.05)	(72.44)	(68.71)	(1,798.51)	(198.92)
12	Extraordinary Item (net of tax expense if any)					
13	Net Profit(+)/ Loss(-) for the period (11-12)	(1490.05)	(72.44)	(68.71)	(1,798.51)	(198.92)
14	Share of profit/(loss) of associates	-			-	-
15	Minority Interest	-			-	-
16	Net Profit(+)/ Loss(-) after taxes, Minority interest and share of profit/(Loss) of associates (13-14-15))	(1490.05)	(72.44)	(68.71)	(1,798.51)	(198.92)
17	Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7,577.00	6577.00	7,577.00	6,577.00
	No of Shares	75,770,000	75,770,000	65,770,000	75,770,000	65,770,000
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	25627.31	25627.31	25627.31	25627.31	25627.31
	Earnings Per Share (EPS)					
19	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(1.97)	(0.10)	(0.10)	(2.37)	(0.30)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(1.97)	(0.10)	(0.10)	(2.37)	(0.30)

For TRANSGENE BIOTEK LTD.



Managing Director

20	Public Shareholding					
	No. of shares	59342098	59342098	59342098	59342098	59342098
	Percentage of shareholding	78.32	78.32	90.23	78.32	90.23
21	Promoters and promoter group Shareholding **	16427902	16427902	6427902	16427902	6427902
	a) Pledged/Encumbered	0.00	0.00	0.00	0.00	0.00
	Number of shares	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
	b) Non-encumbered					
	Number of Shares	16427902	16427902	6427902	16427902	6427902
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	9.77	21.68	9.77

Notes to the Results

- 1) The work on the new cGMP compliant manufacturing facility for the production of DHA is completed. However, because of an accident to one of the scientists involved in the production, commercial operations from this new plant therefore shall commence during the second week of July
- 2) Our team of scientists have demonstrated and monitored the pilot batch production of Tacrolimus at Cipan facility. However, due to unacceptable delay in commencing the commercial operations, the management plans to shift the production of this product at another facility.
- 3) The in-vivo efficacy studies on our oral TrabiOral, an important milestone has produced exciting and remarkable results once aga
- 4) The oncology platforms using mAbs and RNAi are also advancing well and rapidly.
- 5) No. of Investor complaints pending at the beginning of the quarter - NIL; received during the quarter - Nil; resolved during the quarter - NIL; pending unresolved at the end of the quarter - NIL.
- 6) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 30-06-2014
- 7) The audit of the financials pertaining to wholly owned subsidiary Transgene Biotek HK Limited for the year ended 31/3/2014 could not be completed, hence the consolidated financials for the Quarter as well as Year ended 31/3/2014 are not included in this.
- 8) Depreciation has been calculated on the Technologies under development as per the Accounting Standard AS-26 given by the Institute of Chartered Accountants of India which obviously has a bearing on the results.

For and on behalf of the Board of Directors


Dr K Koteswara Rao

Chairman & Managing Director

Place: Hyderabad
Date : 30th June 2014

Annexure IV to Clause 41

Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results

S.No	PARTICULARS	(Rs. In Lakhs)			
		Quarter Ended 31.03.2014 (Audited)	Quarter Ended 31.12.2013 (Unaudited)	Quarter Ended 31.03.2013 (Audited)	For the year ended 31.03.2014 (Audited)
1	SEGMENT REVENUE	Rs.	Rs.	Rs.	Rs.
	a) Segment - A Diagnostic Services	12.99	11.88	13.63	48.42
	b) Segment - B Agri Division	0.00	0.00	0.00	0.00
	c) Segment - C Bulk Drugs Trading	0.00	0.00	0.00	0.00
	d) Segment - D CRO Services	15.26	12.00	0.00	27.26
	e) Segment - E API-DHA	0.00	0.65	47.83	22.43
	Total:	28.25	24.53	61.46	98.11
	Less: Inter Segment Revenue				
	Net Sales/Income From Operation	28.25	24.53	61.46	98.11
2	SEGMENT RESULTS				
	(Profit / Loss Before Tax & Interest from each Segment)				
	a) Segment - A Diagnostic services	1.16	0.18	0.58	4.40
	b) Segment - B Agri Division	0.00	0.00	0.00	0.00
	c) Segment - C Bulk Drugs Trading	0.00	0.00	0.06	0.00
	d) Segment - D ORC Services	5.11	2.35	0.00	13.46
	e) Segment - E API-DHA	-1536.09	-108.52	(72.08)	(1879.02)
	f) R & D Expenses	-0.24	-6.46	(10.08)	(17.36)
	Total Segmental Result	(1530.05)	(112.46)	(81.52)	(1878.51)
	Other Income	40.00	40.00	3.45	80.00
	Total	(1490.05)	(72.46)	(78.07)	(1798.51)
	Less: Interest & Finance Charges	0.00	0.00	(9.37)	0.00
	Less: Unallocable expenses	0.00	0.00	0.00	0.00
	Exceptional items-forex fluctuation(gain)/Loss	0.00	0.00	0	0.00
	Total Profit/Loss Before Tax	(1490.05)	(72.46)	(68.71)	(1798.51)
3	CAPITAL EMPLOYED				
	a) Segment - A Diagnostic services	324.83	324.83	324.83	324.83
	b) Segment - B Agri Division	24090.93	24090.93	24090.93	24090.93
	c) Segment - C Bulk Drugs				
	Total	24415.76	24415.76	24415.76	24415.76

Place: Hyderabad
Date : 30 June 2014


For and on behalf of the Board of Directors
Dr K Koteswara Rao
Chairman & Managing Director

ANNEXURE IX TO CLAUSE 41

(Rs. In Lacs)

Standalone Statement of Assets and Liabilities		As at year ended 31st March 2014 (Audited)	As at year ended 31st March 2013 (Audited)
A EQUITY AND LIABILITIES			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	6,577.00
	(b) Reserves and Surplus	24,045.64	25,627.31
	(c) Money Received against Share Warrants	-	-
	Sub Total - Share Holders' Fund	31,622.64	32,204.31
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	593.21	593.21
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	565.72	569.38
	Sub-Total- Non Current Liabilities	1,158.93	1,162.59
5	Current Liabilities		
	(a) Short Term Borrowings	712.62	1,652.87
	(b) Trade Payables	1,708.37	1,708.54
	(c) Other Current Liabilities	124.86	135.80
	(d) Short-term Provisions	-	-
	Sub-Total- Current Liabilities	2,545.86	3,497.21
	TOTAL EQUITY AND LIABILITIES	35,327.42	36,864.11
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	18,087.37	19,808.92
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,220.10	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,799.51	2,562.95
	(f) Other Non Current Assets	3,198.85	3,198.85
	Sub - total -Non Current Assets	33,305.83	34,790.82
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	7.22	24.77
	(c) Trade Receivables	1,825.06	1,843.34
	(d) Cash and Cash Equivalents	5.17	10.54
	(e) Short-term Loans and Advances	184.14	194.64
	(f) Other Current Assets	-	-
	Sub-total- Current Assets	2,021.59	2,073.29
	TOTAL ASSETS	35,327.42	36,864.11

For and on behalf of the Board of Directors


 Dr K Koteswara Rao
 Chairman & Managing Director

 Place: Hyderabad
 Date : 30th June 2014

SARATH & ASSOCIATES

CHARTERED ACCOUNTANTS

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Clause 41 of the Listing Agreement.

To
Board of Directors of
M/s. Transgene Biotek Limited
Hyderabad.

We have audited the quarterly financial results of **M/s. Transgene Biotek Limited** for the quarter ended 31st March, 2014 and the year to date results for the period 01st April, 2013 to 31st March, 2014 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 read with General Circular 8/2014 dated 4th April 2014 issued by the Ministry of Corporate Affairs and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) have been presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net loss and other financial information for the quarter ended 31st March, 2014 as well as the year to date results for the period from 01st April, 2013 to 31st March, 2014 ***subject to the realisability of the value of investment made in wholly owned subsidiary in the absence of it's audited financial statements for the year, which the company could not provide to us and accordingly we are unable to evaluate and quantify the impact, if any, on the profitability for the year.***

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For Sarath & Associates
Chartered Accountants
Firm Regn.No.005120S


P. Sarath Kumar
Partner (M.No.021755)

Place: Hyderabad
Date: 30.06.2014

Head Office : 4th Floor, Maas Heights, H.No.8-2-577/B, Road No. 8, Banjara Hills, Hyderabad - 500 034.

Ph : Off : +91 40 23354322, 23357090, Fax : 23356716; e-mail : sarathcas@yahoo.com / info@sarathcas.in / sarathcas@rediffmail.com

Branch : Indian Globe Chambers, 4th Floor, DN Road, Mumbai - 400 001; Ph : +91 22 30971830, Fax : 91 22 22621348, e-mail: raorlp@gmail.com